PFE•benzinga•
Pfizer CEO Albert Bourla Emphasizes National Security In US Drug Manufacturing
Summary
Goldman Sachs keeps Neutral on Pfizer, citing unclear product growth plans and focus on M&A amid changing market valuations and national security concerns.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 30, 2025 by benzinga